Global Nasal Drug Delivery Technology Market - 2025-2033

The global nasal drug delivery technology market reached US$ 81.69 billion in 2024 and is expected to reach US$ 136.97 billion by 2033, growing at a CAGR of 6.7% during the forecast period 2025-2033.

Nasal drug delivery technology refers to the administration of drugs through the nasal cavity to achieve therapeutic effects. This route of drug delivery is increasingly being used for its convenience, efficiency, and ability to bypass the gastrointestinal system and hepatic first-pass metabolism, which can reduce side effects and improve drug bioavailability. Nasal drug delivery technology involves the use of nasal sprays, powders and aerosols to deliver drugs directly into the bloodstream via the nasal mucosa. This method is particularly beneficial for the delivery of peptides, proteins, vaccines and other drugs that may not be effective when administered orally due to degradation in the gastrointestinal tract or poor absorption.

The market demand for nasal drug delivery technology is growing rapidly due to its non-invasive nature, convenience and improved patient compliance. The adoption rate of these technologies is being driven by several factors including increasing applications in chronic disease management, for instance, according to the Centers for Disease Control and Prevention, an estimated 129 million people in the US have at least 1 major chronic disease. According to the World Health Organization, by 2030, 1 in 6 people in the world will be aged 60 years or over, this aging population requires easier and more acceptable treatment options, which increases the demand for nasal drug delivery technology.

Market Dynamics: Drivers & Restraints

Rising advancements in nanotechnology

The rising advancements in nanotechnology are significantly driving the growth of the nasal drug delivery technology market and are expected to drive the market over the forecast period by enabling the development of more efficient and targeted drug delivery systems. These innovations enhance the effectiveness of drugs delivered through the nasal route by improving their stability, bioavailability and patient compliance.

For instance, in October 2024, researchers from the Institute of Nano Science and Technology (INST), Mohali, developed a novel drug delivery system to treat Central Nervous System Tuberculosis (CNS-TB). This cutting-edge method delivers anti-tuberculosis (TB) drugs directly to the brain through the nasal route, overcoming the limitations posed by the blood-brain barrier (BBB).

Nanotechnology involves the use of nanoparticles that can carry drugs directly across the nasal mucosa into the bloodstream. These nanoparticles can protect drugs from degradation, enhancing their stability and bioavailability. This is particularly beneficial for peptides and proteins, which are typically unstable when administered orally.

Additionally, in November 2024, Virpax Pharmaceuticals, Inc. was granted an extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS). This collaboration is for the continued development of Virpax's product candidate, NES100, an intranasal peptide, for the management of acute and chronic non-cancer pain. NES100 is an enkephalin drug product based on a type of nanotechnology delivery approach. Enkephalin is a naturally occurring (endogenous) peptide that is not easily administered in its original form.

Adverse effects and safety concerns

Adverse effects and safety concerns are significant challenges hampering the growth of the nasal drug delivery technology market. These issues can impact the acceptability and adoption of nasal drug delivery systems by both patients and healthcare providers. Nasal drug delivery can sometimes cause irritation or allergic reactions in the nasal mucosa. This can lead to discomfort and patient reluctance to use nasal sprays or powders. Localized side effects such as dryness, sneezing or nasal congestion are common issues with nasal drug delivery technologies.

For instance, the use of corticosteroids in nasal sprays for managing allergies can result in local irritation, leading to nosebleeds or a burning sensation in the nasal passages. Such adverse effects can discourage patients from continuing treatment.

Although nasal delivery minimizes first-pass metabolism, there is still a risk of systemic absorption, especially for drugs that are intended to act locally. This can lead to unintended systemic side effects, which can limit the use of certain drugs in nasal formulations. For instance, for drugs intended for local action like nasal decongestants, systemic absorption may still occur, potentially leading to cardiovascular effects such as increased heart rate and blood pressure.

Segment Analysis

The global nasal drug delivery technology market is segmented based on dosage form, application, distribution channel and region.

Application:

The respiratory diseases segment is expected to dominate the nasal drug delivery technology market share

Nasal drug delivery systems are highly effective for treating allergic rhinitis and asthma, which are common respiratory conditions. These conditions require frequent medication administration, and nasal sprays are particularly suitable due to their quick onset of action and localized effects. Nasal corticosteroids are the primary drugs used in this segment, offering targeted anti-inflammatory action directly to the nasal mucosa, which minimizes systemic side effects.

For instance, in January 2023, Airsupra (albuterol/budesonide), formerly known as PT027, which is developed by AstraZeneca and Avillion, was approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older. Airsupra is a fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS) in the US.

The nasal route allows for quick absorption of drugs into the bloodstream, which is particularly advantageous for managing acute symptoms of respiratory diseases like asthma attacks. Drugs administered via the nasal route can bypass the gastrointestinal system and avoid the first-pass metabolism in the liver, ensuring higher bioavailability and faster therapeutic effects.

Geographical Analysis

North America is expected to hold a significant position in the nasal drug delivery technology market share

Major pharmaceutical companies and research institutions in North America especially in the United States, are investing heavily in the development and commercialization of nasal drug delivery systems. Companies like Pfizer, Johnson & Johnson, Amneal Pharmaceuticals, Inc. and other emerging players have been at the forefront, with nasal drug formulations being a key component of their respiratory disease management strategies by FDA approvals.

For instance, in April 2024, Amneal Pharmaceuticals, Inc. announced the availability of Over the Counter (OTC) Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg, following Abbreviated New Drug Application approval from the U.S. Food and Drug Administration (FDA). Amneal's Naloxone HCI Nasal Spray, manufactured in the U.S., is a generic equivalent to OTC NARCAN HCI Nasal Spray, a medication that is widely used to help treat drug overdose from opioids, including heroin, fentanyl and prescription opioid medications.

Additionally, in September 2024, Renaissance Lakewood, LLC manufactured neffy. The FDA approved and became the first and only needle-free, intranasal spray treatment for Type I allergic reactions, including anaphylaxis in adults and children. neffy is an easy-to-carry and easy-to-use epinephrine medication alternative to needle-based treatments for potentially life-threatening allergic reactions. neffy marks the first regulatory approval worldwide for epinephrine delivered as an intra-nasal spray.

Asia-Pacific is growing at the fastest pace in the nasal drug delivery technology market

The healthcare infrastructure in the Asia-Pacific region has been rapidly improving. Countries like India, China, Japan and South Korea are investing heavily in healthcare, including the establishment of new medical facilities and research centers. For instance, according to the India Brand Equity Foundation (IBEF), under the PLI scheme for Medical Devices, till now, a total of 26 projects have been approved, with a committed investment of US$ 147 million. These rising investments and developments have facilitated the adoption of advanced drug delivery technologies, including nasal drug delivery systems.

In March 2024, Aurobindo Pharma added 1.28% to Rs 1,002.05 after the drug maker received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Mometasone Furoate Monohydrate Nasal Spray. The approved drug is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Nasonex Nasal Spray of Organon LLC. The product will be launched in Q1 FY25. Mometasone Furoate Monohydrate Nasal Spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis, in adults and pediatric patients 2 years of age and older.

The APAC region is witnessing rapid adoption of new drug delivery technologies, including nanotechnology and controlled release systems for nasal drug delivery. Companies in the region along with strategic partnerships and mergers, innovating and distributing nasal formulations that cater to regional needs. For instance, Altamira Therapeutics Ltd. announced that its associate company Altamira Medica Ltd. agreed with its partner Nuance Pharma, Shanghai, China to extend the territory covered by their exclusive license and distribution agreement for Bentrio nasal spray by several countries across South East and East Asia.

Competitive Landscape

The major global players in the nasal drug delivery technology market include Pfizer Inc., Becton, Dickinson and Company, AstraZeneca PLC, AptarGroup, Inc., MetP Pharma AG, GlaxoSmithKline Inc., Hikma Pharmaceuticals PLC, Currax Pharmaceuticals LLC., Tonix Medicines, Inc., Johnson & Johnson and among others.

Key Developments

• In October 2024, Aero Pump and Resyca announced their collaboration in the launch of the innovative Ultra Soft Nasal Pump Spray. Available for licensing immediately, this co-developed system represents a new frontier in nasal drug delivery, offering enhanced delivery efficiency, precision and comfort for users.
• In April 2024, Aptar Pharma launched APF Futurity, its first metal-free, multidose nasal spray pump developed to deliver nasal saline and other comparable over-the-counter (OTC) formulations. APF Futurity is made from polyolefin materials with no metal parts or recycling disruptors, thereby minimizing separation efforts in recycling streams and supporting a higher quality of recyclates.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global nasal drug delivery technology market report delivers a detailed analysis with 62 key tables, more than 54 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.